Opinion|Videos|July 10, 2024
Collaborative Education for CAR T-Cell Therapy
The panel concludes its discussion with insights on practices for educating health care teams on CAR T-cell therapy administration, highlighting the evolving role of advanced practice providers.
Advertisement
Episodes in this series
Video content above is prompted by the following question:
- Please provide your final thoughts on the unmet needs and future directions for enhancing the transition of care and fostering stronger partnerships between academic and community settings in the field of CAR T-cell therapy.
Advertisement
Related to this article
Updated NCCN Guidelines for multiple myeloma add a dedicated MRD testing framework and expand recommended MRD assessment timepoints.
Experts discussed whether CAR T cells or bispecific antibodies should be used first in relapsed/refractory multiple myeloma at the 2026 SOHO Annual Meeting.
Advertisement
Advertisement
Trending on CancerNetwork
1
Key Takeaways for Multidisciplinary Lung Cancer Care From WCLC 2026
2
CELMoDs After T-Cell–Engaging Therapy in Multiple Myeloma
3
FDA Approves Imlunestrant Combo in ESR1-Mutated Breast Cancer
4
Pembrolizumab/Enfortumab Vedotin Earns Positive CHMP Opinion in MIBC
5